Back to today’s briefing

Story perspectives

U.S. to Negotiate Prices for 15 Essential Drugs

1/17/2025

30 7

Summary

Government Drug Negotiations

Starting in 2025, the U.S. government will negotiate prices for 15 essential drugs, including popular medications like Ozempic and Wegovy, under Medicare. This groundbreaking move, part of the Inflation Reduction Act, seeks to ease the financial burden on beneficiaries, with new prices rolling out in 2027. Drug manufacturers face a crucial decision by February 2025 on whether to join the negotiations.

Summary

Teva Sues Biden

Teva Pharmaceuticals is taking a stand against the Biden administration, filing a lawsuit over the Medicare Drug Price Negotiation Program. The company argues that the program stifles innovation and misreads the Inflation Reduction Act, particularly targeting the definitions of eligible drugs that threaten the future of its products, Austedo and Austedo XR, set for negotiation in 2025.

History

Historical Context

Starting in 2025, the U.S. will negotiate prices for 15 essential drugs under Medicare, a significant shift in pharmaceutical policy. Historically, the U.S. has grappled with high drug prices and limited regulation. Previous attempts, like Medicare Part D in 2006, allowed private negotiations but did not control costs, highlighting the ongoing struggle for affordable healthcare in America.

1 of 3

Government Drug Negotiations

Starting in 2025, the U.S. government will negotiate prices for 15 essential drugs, including popular medications like Ozempic and Wegovy, under Medicare. This groundbreaking move, part of the Inflation Reduction Act, seeks to ease the financial burden on beneficiaries, with new prices rolling out in 2027. Drug manufacturers face a crucial decision by February 2025 on whether to join the negotiations.

1 / 3